Clinical trials: Chronic Diseases
Urticaria
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
This First Time in Human (FTIH) study, which will be performed in three parts, is designed to investigate the safety, local tolerability, pharmacokinetics and pharmacodynamics after single and repeat topical applications of up to…
- Trial name
- NCT02424799
- Testing
- GSK2646264 0.5% topical cream, GSK2646264 1% topical cream
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Diabetic Kidney Disease, Chronic Kidney Disease
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
The purpose of this study is to evaluate the long-term safety, efficacy, and durability in participants with chronic kidney disease (CKD) who received up to four REACT injections, delivered percutaneously into either the same or…
- Trial name
- NCT06790498
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prokidney
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)
Tumor Registry of Lymphatic Neoplasia
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
- Trial name
- TLN-Registry (NCT00889798)
- Volunteers
- 3,795 people
- Sponsor
- iOMEDICO AG
Pain, Low Back Pain
An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants
The purpose of this study is to evaluate the efficacy, safety and to explore the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of…
- Conditions
- Pain, Low Back Pain, Back Pain, Osteoarthritis, Knee
- Trial name
- NCT01124604
- Testing
- Tapentadol Hydrochloride
- Where
- 19 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and to evaluate the safety and tolerability of LDV/SOF FDC and sofosbuvir…
- Trial name
- NCT02738333
- Testing
- LDV/SOF, SOF, RBV
- Where
- 37 sites in Japan
- Volunteers
- 239 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus (HCV)
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human…
- Trial name
- VOYAGE-2 (NCT03235349)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 34 sites in China, South Korea
- Volunteers
- 160 people
- Sponsor
- AbbVie
Gastritis
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495
To Evaluate the Efficacy and Safety of CKD-495
- Trial name
- NCT04255589
- Testing
- CKD-495 75mg, Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
- Where
- 17 sites in South Korea
- Volunteers
- 242 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Liver Disease, Thrombocytopenia
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
The primary purpose of this study is to compare the efficacy of lusutrombopag with placebo for the treatment of thrombocytopenia in patients with chronic liver disease who are undergoing elective invasive procedures.
- Trial name
- L-PLUS 2 (NCT02389621)
- Testing
- Lusutrombopag
- Volunteers
- 215 people
- Sponsor
- Shionogi
COPD
TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
Efficacy of TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on lung stiffness reduction assessed through area under the reactance curve (AX) using oscillometry in chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04671355
- Testing
- Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg, Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg
- Sponsor
- Chiesi Farmaceutici S.p.A.
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
The KHENEREXT Study
This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation who completed study KH176-202.
- Conditions
- Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Trial name
- NCT04604548
- Testing
- Oral administration of 100 mg KH176 twice daily
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Khondrion BV
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT06598943
- Testing
- Eltrekibart, Mirikizumab
- Where
- 207 sites in United States, Argentina and 19 more
- Volunteers
- 143 people
- Sponsor
- Eli Lilly and Company
Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
- Trial name
- NCT00097435
- Testing
- Albuferon, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 115 people
- Sponsor
- Human Genome Sciences Inc.
End Stage Renal Disease
Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration
Today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the…
- Trial name
- NCT03499691
- Testing
- Theranova 500 medium cut-off dialyzer, Hemodiafiltration
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Vantive Health LLC
Heart Failure
Chronic Heart Failure Therapy Optimization With CardioRenal Remote Monitoring System (HERMESHF)
This clinical study evaluates short-term feasibility and safety of CardioRenal ExpHeart in patients with worsening heart failure with reduced ejection fraction to optimize pharmacological heart failure treatment.
- Trial name
- HERMESHF (NCT04050904)
- Testing
- ExpHeart
- Volunteers
- 30 people
- Sponsor
- CardioRenal
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
End Stage Renal Disease
A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement
The ability to selectively control blood flow through an arteriovenous (AV) graft only when it is needed for dialysis may reduce the current repetitive complications such as thrombosis, venous hypertension post-dialysis bleeding…
- Trial name
- NCT01644526
- Testing
- Hemoaccess Valve System
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Diaxamed LLC
Chronic Renal Failure, Anemia
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis
The purpose of this study is to evaluate the safety,efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) who are on hemodialysis.
- Trial name
- NCT02366325
- Testing
- EPO-018B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.
- Trial name
- ENLIGHTEN 1 (NCT05219968)
- Testing
- LYR-210, Background Therapy
- Where
- 55 sites in United States, Austria and 3 more
- Volunteers
- 196 people
- Sponsor
- Lyra Therapeutics
Iron Deficiency Anaemia, Chronic Kidney Disease
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron…
- Trial name
- FIND-CKD (NCT00994318)
- Testing
- FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
- Where
- 19 sites in United States, Australia and 17 more
- Volunteers
- 626 people
- Sponsor
- Vifor Pharma
Knee Osteoarthritis
Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments.
This is a phase 3, multicentre, prospective, single-blind on principal efficacy criterion, 2 parallel groups, randomized, controlled clinical study comparing efficacy and safety of actiTENS versus systemic level 2 analgesics…
- Trial name
- ArthroTENS (NCT03902340)
- Testing
- ActiTENS, Level 2 Analgesic Treatments
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Sublimed
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.